Justin F Creeden, Jonathan Sevier, Jian-Ting Zhang, Yakov Lapitsky, F Charles Brunicardi, Ge Jin, John Nemunaitis, JingYuan Liu, Andrea Kalinoski, Donald Rao, Shi-He Liu
Exosomes continue to attract interest as a promising nanocarrier drug delivery technology. They are naturally derived nanoscale extracellular vesicles with innate properties well suited to shuttle proteins, lipids, and nucleic acids between cells. Nonetheless, their clinical utility is currently limited by several major challenges, such as their inability to target tumor cells and a high proportion of clearance by the mononuclear phagocyte system (MPS) of the liver and spleen. To overcome these limitations, we developed "Smart Exosomes" that co-display RGD and CD47p110-130 through CD9 engineering (ExoSmart )...
February 29, 2024: Journal of Controlled Release